Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Other Accumulated Expenses readings, the most recent being $2.1 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 41.66% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 41.66% increase, with the full-year FY2025 number at $405000.0, down 86.88% from a year prior.
  • Other Accumulated Expenses hit $2.1 million in Q4 2025 for Enanta Pharmaceuticals, up from $405000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $14.4 million in Q1 2022 to a low of $405000.0 in Q3 2025.
  • Median Other Accumulated Expenses over the past 5 years was $2.3 million (2025), compared with a mean of $3.5 million.
  • Biggest five-year swings in Other Accumulated Expenses: surged 1295.16% in 2022 and later tumbled 86.88% in 2025.
  • Enanta Pharmaceuticals' Other Accumulated Expenses stood at $1.1 million in 2021, then soared by 541.91% to $6.9 million in 2022, then tumbled by 63.76% to $2.5 million in 2023, then tumbled by 41.7% to $1.4 million in 2024, then surged by 41.66% to $2.1 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $2.1 million (Q4 2025), $405000.0 (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.